Healthcare Industry News: migraine
News Release - November 8, 2011
Nautilus Neurosciences Appoints Peter Lankau as Executive ChairmanBEDMINSTER, NJ--(Healthcare Sales & Marketing Network)- Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company headquartered in Bedminster, New Jersey, announced today that Peter A. Lankau has joined the company as Executive Chairman of the Board of Directors. Mr. Lankau will have an active role in the company and will focus primarily on business strategy and portfolio development. Nautilus, whose marketed migraine treatment product, CAMBIA™ (diclofenac potassium for oral solution), was launched in 2010, is a private equity backed company sponsored by Tailwind Capital Partners of New York and Galen Partners of Stamford, Connecticut.
"We are all excited to welcome Peter to the Nautilus team," said William Maichle, Chief Executive Officer of Nautilus. "I have known Peter for many years and could not think of a better partner to assist the management team in the growth of Nautilus."
Commented Geoff Raker, Board member and Managing Director at Tailwind Capital, the founding investor in Nautilus, "We are delighted to have Peter join the Nautilus team and our Board of Directors. His experience in leading growth-oriented companies will help propel Nautilus' future growth as a significant specialty pharma company."
Zubeen Shroff, Managing Partner at Galen Partners, and a Board member said, "The continued growth of CAMBIA and Nautilus' future business development opportunities are certain to benefit from Peter's experience."
Mr. Lankau said, "I am excited to be joining a management and investor team that has brought to market such a novel and meaningful migraine therapy as CAMBIA. I am looking forward to helping CAMBIA become a significant therapy for patients who need more from their migraine treatment as well as growing the company's portfolio to enable Nautilus to become a significant player in neurology." With Mr. Lankau's experience as a business leader, Nautilus is poised to execute a focused business development strategy aimed at building its neurology franchise in addition to CAMBIA.
Mr. Lankau is an experienced biopharmaceutical executive with extensive experience in developing and commercializing pharmaceutical products. As President and CEO of Endo Pharmaceuticals Inc., he led the growth of the company during its transformation from a private equity-backed firm into an integrated specialty pharmaceutical business with leadership in pain management, including a focus in migraine. Most recently, he was CEO of Logical Therapeutics, Inc., a development stage biopharmaceutical company developing drug candidates for inflammatory disease. He is also a member of Logical's Board of Directors.
Nautilus' lead product, CAMBIA, is a novel treatment for acute migraine in adults. CAMBIA is the only prescription nonsteroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine. Engineered using Dynamic Buffering Technology ™ (DBT), CAMBIA is specifically designed for fast, effective relief from symptoms of migraine. Designed to treat the underlying pathophysiology of migraine, CAMBIA reaches peak blood levels within 15 minutes and provides equally rapid relief from migraine. The Food and Drug Administration (FDA) approval of CAMBIA was based on two Phase 3 placebo-controlled trials showing that CAMBIA was superior to placebo in all four FDA-mandated coprimary end points for migraine -- pain, nausea, photophobia and phonophobia. Both studies also showed that reduction in pain intensity was significantly greater in the CAMBIA group than in the placebo group as early as 15 minutes following treatment, and headache response rates were superior to placebo for up to 24 hours. For more information on CAMBIA, please visit www.cambiarx.com.
Nautilus Neurosciences, Inc.
Nautilus Neurosciences, Inc. is a neurology-focused specialty pharmaceutical company committed to providing the healthcare community with medically relevant products and services that directly benefit those affected by neurologic disorders. Nautilus is sponsored by Tailwind Capital and Galen Partners. For more information on Nautilus, please visit www.nautilusneurosciences.com.
Tailwind Capital Partners
Tailwind Capital Partners is a leading private equity firm investing in growth-oriented middle market companies in healthcare, business services, and media/communications. Tailwind partners with management teams to build businesses through organic growth, strategic acquisition, and operational improvement. The firm currently has more than $1 billion under management. Representative Tailwind investments include VersaPharm (generic pharmaceuticals), Aircast (orthopedic devices), Freedom Innovations (prosthetic devices), SDI Health (healthcare analytics), TowerCo (wireless infrastructure), Archway (marketing logistics), and Trover Solutions (insurance services). For more information about Tailwind, please visit www.tailwind.com.
Galen Partners is a leading late-stage venture capital investment firm based in Stamford, Connecticut. The firm focuses on growth equity investments in healthcare technology enabled services, medical devices, and specialty pharmaceutical companies. With nearly $1 billion under management raised through five funds, Galen has invested in more than 70 companies since 1990. Galen's specialty pharmaceutical investments include Acura Pharmaceuticals, Dow Pharmaceutical Sciences (acquired by Valeant Pharmaceuticals in 2008), JDS Pharmaceuticals (acquired by Noven Pharmaceuticals in 2007), and Taro Pharmaceuticals. The firm continues a tradition of strategic collaboration and partnership with its portfolio company management teams to build healthcare market leaders. For more information, please visit Galen's website at www.galen.com.
For further information regarding business development at Nautilus, please contact Peter Lankau at email@example.com, Geoff Raker at firstname.lastname@example.org or Zubeen Shroff at email@example.com.
Source: Nautilus Neurosciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.